Jeremy Ryan
Papers
1
Total Citations
8
H-Index
1
About
Jeremy Ryan is a translational cancer researcher whose work focuses on improving precision therapy for esophageal cancers, a disease responsible for thousands of deaths annually. His most cited study, "Metabolomic and BH3 profiling of esophageal cancers: novel assessment methods for precision therapy" (2018, 8 citations), addresses the critical challenge of predicting patient response to neoadjuvant chemoradiotherapy (nCRT) prior to esophagectomy. By integrating metabolomic analysis with BH3 profiling—a technique that measures apoptotic priming—Ryan developed novel assessment methods to identify which patients are likely to achieve a pathological complete response (no residual tumor). This work is particularly impactful because it moves beyond traditional staging to offer functional, molecular biomarkers that could guide treatment decisions, potentially sparing non-responders from ineffective, toxic therapies. Although his citation count is still growing, Ryan’s contributions are notable for bridging the gap between laboratory science and clinical oncology, offering a personalized approach to a cancer with rising incidence and poor prognosis. His research exemplifies how combining metabolic and apoptotic profiling can refine precision medicine in one of the most challenging solid tumors.
Research Focus
Key Achievements
Top Papers
- 1